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The Nef protein of HIV-1 mediates immune
evasion by relocating major histocompatibility
complex (MHC) molecules and the immune
costimulatory molecules CD80 and CD86
away from the monocytic cell surface. We de-
scribe a two-pronged mechanism by which
Nef removes CD80 and CD86 from the cell
surface.While MHCI, CD80, and CD86 are all in-
ternalized via a dynamin-independent pathway,
the endocytic mechanism used for costimula-
tory molecules is distinct fromMHCI relocation.
Nef expression results in the activation and ac-
tin-dependent translocation of Src kinase to the
cell periphery. At the cell surface, Src promotes
Rac activation via TIAM, a guanine nucleotide
exchange factor for Rac. Nef also binds to the
cytosolic tails of CD80 and CD86, triggering
their endocytosis via Rac-based actin polymer-
ization. These data reveal the use of an unusual
molecular mechanism triggered in the host cell
by HIV to affect its viral immune evasion strat-
egy and suggest approaches for its subversion.
INTRODUCTION
The HIV-1 nonstructural, multidomain protein Nef plays
a key role in viral pathogenicity (Kestler et al., 1991; Ma-
riani et al., 1996; Greenway et al., 2003). Nef expressed
in infected macrophages can prevent host-cell death to
create a persistent virus reservoir and can signal the in-
fected macrophage to recruit and activate T cells, making
them available and susceptible for virus spread (Geleziu-
nas et al., 2001; Swingler et al., 1999, 2003; Wolf et al.,
2001). Nef also potentially helps evade immunity by reduc-
ing surface levels of both MHC class I (MHCI) and MHC
class II (MHCII) on infected cells.
We have recently observed that, in macrophages and
dendritic cells, Nef binds to and mediates redistribution
of the immune costimulatory molecules of the B7 family,CeCD80 and CD86, away from the antigen-presenting cell
surface, resulting in inhibition of T cell priming. The mech-
anisms of action of Nef on CD80 and CD86 are likely to be
distinct from those mediating MHCI internalization, since
mutations in Nef that prevent MHCI downmodulation do
not affect CD80 and CD86 internalization (Chaudhry
et al., 2005).
Nef modulates the infected cell surface mainly by influ-
encing endocytic trafficking of target molecules such as
MHCI, MHCII, or CD4 (Mariani and Skowronski, 1993)
via different pathways. There is a growing list of endocytic
pathways involving the coat proteins clathrin or caveolin
that use the common scissoring agent dynamin (Henley
et al., 1998) and a range of clathrin- and caveolin-indepen-
dent mechanisms that do not involve dynamin (Conner
and Schmid, 2003; Johannes and Lamaze, 2002). Such
an overlapping diversity of endocytic pathways provides
a cornucopia of targets for microbial subversion. For in-
stance, Nef-mediated CD4 relocation is based on a dyna-
min-dependent process, while relocation of MHCI by Nef
is dynamin independent and relies on ADP ribosylation
factor-6 (Arf-6) and phosphatidylinositol 3-kinase (PI3K)
(Blagoveshchenskaya et al., 2002).
We have therefore investigated the processes by which
Nef mediates the redistribution of CD80 and CD86 in
human monocytic cells. We find that, while Nef removes
surface MHCI, CD80, and CD86 by internalization via a
dynamin-independent pathway, the endocytic mecha-
nism used for removal of CD80 and CD86 is distinct
from the one used for MHCI relocation. It involves Nef
binding to the cytoplasmic tails of these target proteins
to couple them to a cholesterol-insensitive endocytic
pathway. This occurs by Nef-mediated activation of a cas-
cade of signaling molecules implicated in actin polymeri-
zation at the plasma membrane via Src phosphorylation
and Rac activation.
RESULTS
HIV-1 Nef Relocates Cell-Surface MHCI, CD80,
and CD86 to Intracellular Compartments
To examine the loss of surface resident proteins from Nef-
expressing cells, we transfected a wild-type (WT) nef genell Host & Microbe 1, 37–49, March 2007 ª2007 Elsevier Inc. 37
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Nef-Mediated Removal of Surface CD80 and CD86Figure 1. HIV-1 Nef Protein Relocates
Cell-Surface CD80 and CD86 to Intra-
cellular Compartments
(A) U937 cells, transfected to express eGFP or
Nef-eGFP before labeling cell-surface MHCI,
CD80, or CD86 with biotinylated antibodies,
were chased for various times and subjected
to flow cytometric detection of either sur-
face or total label postpermeabilization. Mean
fluorescence intensities were calculated for
eGFP-expressing cells and normalized to the
starting intensities for expression as percent-
age residue of surface-labeled molecules.
The data show mean ± SD values from three
independent experiments.
(B) Transfected U937 cells expressing F2-Nef-
eGFP or eGFP were labeled for surface MHCI,
CD80, or CD86 as above and cultured further
for 0 hr or 12 hr as indicated before being fixed
and imaged by confocal microscopy. Insets
are 23 magnified and show grayscale images
for each color as well as for merged colors.
Scale bar, 10 mm.(F2-nef) cloned from an Indian clinical isolate (Chaudhry
et al., 2005) into the humanmonocytic cell line U937, using
a plasmid vector expressing F2-Nef and enhanced green
fluorescent protein (eGFP). The disappearance of MHCI,
CD80, and CD86 from the cell surface over time was
followed by labeling surface molecules with biotinylated
antibodies, and chasing for various times before flow
cytometric detection of residual surface label with fluoro-
phore-labeled streptavidin for calculation of the propor-
tions of surface molecules internalized over the chase pe-
riod. To determine whether the label lost from the surface
was quantitatively retained intracellularly, cells were also
permeabilized and stained to determine the total amount
of cell-associated antibody at each chase time point.
The data show that, in the absence of Nef, CD80 and
CD86 are stably resident at the cell surface (Figure 1A).
In the presence of Nef, however, cell-surface MHCI,
CD80, and CD86 were internalized, causing a ten-fold re-
duction in surface levels (Figure 1A). While a significant
fraction of surface MHCI was lost by 4–6 hr, comparable
loss of CD80 and CD86 occurred by 10 hr.
We also confirmed the Nef-mediated internalization of
cell-surface MHCI, CD80, and CD86 by localizing anti-
body-labeled surface molecules via confocal microscopy.
By 12 hr post-surface-labeling, MHCI, CD80, and CD8638 Cell Host & Microbe 1, 37–49, March 2007 ª2007 Elseviermolecules had disappeared from the surface of Nef-
expressing but not of control eGFP-expressing U937 cells
and were relocated in perinuclear compartments along
with the Nef-eGFP fusion protein (Figure 1B).
Nef-Mediated Downmodulation of CD80 and CD86
Is Insensitive to Inhibitors of Dynamin, PI3 Kinase
Activity, and Depletion of Cholesterol Levels
It has been reported that Nef-mediated CD4, but not
MHCI, internalization is dynamin dependent (Le Gall
et al., 2000). We therefore tested the ability of the domi-
nant-negative K44A mutant of dynamin-2 (DN-dyn), or of
a short interfering RNA for dynamin-2 (sh-Dyn; Gomez
et al., 2005), to inhibit Nef-mediated MHCI, CD80, and
CD86 downmodulation in cotransfection assays. Nef-
mediated relocation of MHCI, or CD80 and CD86, was
unaffected by the presence of either DN-dyn or sh-Dyn
(Figure 2A). In independent experiments we found that
neither CD80 nor CD86 downmodulation was affected
by expression of DN-eps15 (ED95/295; data not shown),
an inhibitor of clathrin-mediated endocytosis (Benmerah
et al., 2000). At the same time, however, DN-dyn, and
sh-Dyn and DN-eps15, significantly inhibited dynamin-
dependent transferrin (Tf) endocytosis in the same cellsInc.
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Nef-Mediated Removal of Surface CD80 and CD86Figure 2. Nef-Mediated Relocation of CD80 and CD86 Is Independent of Dynamin, Cholesterol, and PIK Activity but Involves Actin,
Rac, and CRIB Domain Proteins
(A) U937 cells were cotransfected with various plasmids and stained for cell-surface MHCI, CD80, or CD86 and plasmid expression markers. Single-
color histograms show staining profiles of cells expressing control HAp, F2-Nef-HAp, DN-dyn-eGFP/sh-dyn-eGFP, or F2-Nef+DN-dyn-eGFP/
sh-dyn-eGFP. Gray curves are isotype controls.
(B) Recombinant Nef (nef) or BSA (c) were cytosolically loaded into U937 cells by the Chariot reagent for MBCD treatment, or U937 cells were trans-
fected to express either eGFP or F2-Nef-eGFP (nef) for Wm treatment. Cells were stained with biotinylated antibodies to MHCI (left panels), CD80
(middle panels), or CD86 (right panels), and chased for indicated times with indicated MBCD or Wm concentrations before quantifying residual
cell-surface label. Data are shown as percentage of mean residual surface label in Nef-expressing cells versus control cells at each time point.
(C) U937 cells transfected to express either eGFP (yellow shaded curves) or F2-Nef-eGFP (Nef) were treated with nocodazole (50 mM), jasplakinolide
(2 mM), latrunculin B (2 mM), or cytochalasin B (5 mM), and surface levels of MHCI, CD80, and CD86 were analyzed. Single-color histograms of gated
eGFP+ cells are shown. Gray curves are isotype controls.
(D–G) U937 cells were cotransfected with various plasmids and stained for cell-surface MHCI, CD80, or CD86 and plasmid expression markers. Sin-
gle-color histograms show staining profiles of cells expressing control HAp (yellow curves), F2-Nef-HAp, DN-Rho-eGFP/DN-cdc42-eGFP/DN-Rac1-
eGFP/CRIB-eGFP, or F2-Nef+ DN-Rho-eGFP/DN-cdc42-eGFP/DN-Rac1-eGFP/CRIB-eGFP as indicated. Gray curves are isotype controls.
(H) U937 cells were cotransfected with either Rac-specific siRNA or a control nonspecific sequence along with a marker Thy-1-expressing plasmid.
Magnetic sorting of Thy-1+ cells was followed by Western blot analyses of cell lysates with the indicated antibodies.
(I) U937 cells were cotransfected with indicated constructs and stained for surface MHCI, CD80, or CD86. Single-color histograms show staining
profiles of cells expressing eGFP (yellow curves), F2-Nef-eGFP, or F2-Nef-eGFPwith either irrelevant c-siRNA or Rac-siRNA (detected by expression
of myc-p from a cotransfected myc-p-bearing plasmid). Gray curves are isotype controls.Cell Host & Microbe 1, 37–49, March 2007 ª2007 Elsevier Inc. 39
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Nef-Mediated Removal of Surface CD80 and CD86as expected (data not shown), consistent with inhibition of
clathrin- and dynamin-dependent endocytic processes.
We next examined whether Nef-mediated downmodu-
lation of MHCI and CD80/CD86 was sensitive to perturba-
tion of levels of membrane cholesterol, a major determi-
nant of many endocytic processes (Parton and Richards,
2003). A strategy was devised to detect the effects of
Nef on MHCI, CD80, and CD86 in the shortest possible
time, by delivering purified recombinant Nef into U937
cells with a commercial antennapedia-like carrier peptide
(Chariot) shown to mediate efficient peptide/protein deliv-
ery into the cytosol at 4C (Dani et al., 2004). The recombi-
nant Nef was likely to be myristoylated and functional,
since the intracellular distribution of this recombinant
Nef was similar to that of transfected F2-Nef and unlike
the diffuse distribution of transfected myristoylation-
deficient G2A-F2-Nef (Figure S1 in the Supplemental
Data available with this article online). Cells were then
stained with biotinylated antibodies to MHCI, CD80, or
CD86 and chasedwith or without the cholesterol chelating
agent methyl-b-cyclodextrin (MBCD) (1.5 mM or 5 mM)
before detecting residual surface label with fluorophore-
labeled streptavidin. By 8 hr post-Nef delivery, surface
levels of MHCI, CD80, and CD86 had declined by >70%.
MBCD delayed MHCI internalization without having any
effect on the loss of surface CD80 or CD86 (Figure 2B).
Nef-mediated MHCI relocation is also reported to de-
pend on phosphatidylinositol kinase (PIK) activity, al-
though it is unclear if PI3K is specifically needed (Larsen
et al., 2004). We therefore tested the effect of wortmannin
(Wm), a PI3K inhibitor, on Nef-mediated loss of cell-sur-
face MHCI, CD80, and CD86. At a lowWm dose (100 nM),
Nef-mediated loss of surface MHCI, CD80, or CD86 was
not affected, while at a higher Wm concentration (1 mM),
Nef-mediated loss of MHCI was blocked, but loss of
CD80 and CD86 remained unaffected (Figure 2B).
Together, these data indicate differences in the endo-
cytic mechanisms for Nef-mediated relocation of MHCI
and CD80/CD86 since, while both are mediated via
dynamin-independent pathways, they are differentially
sensitive to cholesterol depletion and to PIK inhibition.
Nef-Mediated Redistribution of CD80 and CD86 Is
Dependent upon Mediators of Actin Polymerization
Wenext tested inhibitors of actin polymerization, latruncu-
lin B (LB) and cytochalasin B (CB), or an inhibitor of actin
depolymerization, jasplakinolide (JPL), as well as nocodo-
zole (NZ), an inhibitor of tubulin polymerization, for their ef-
fects on Nef-mediated downmodulation of CD80, CD86,
and MHCI. While NZ had no effect on Nef-mediated re-
duction in surface MHCI, CD80, or CD86 levels in U937
cells, the actin-directed agents, LB, CB, and JPL, inhibited
Nef-mediated loss of surface CD80 and CD86, but not of
MHCI (Figure 2C). The drugs had no detectable effects
on cell viability over the assay duration (Figure S2).
We examined the role of molecules regulating actin
polymerization such as Rac, RhoA, cdc42, and ARP2/3
interacting proteins containing the CRIB domain (such
as WASP) (Jaffe and Hall, 2005), by using plasmids carry-40 Cell Host & Microbe 1, 37–49, March 2007 ª2007 Elsevier Ining DN mutants of these genes (DN-Rac1, DN-RhoA,
DN-Cdc42, and CRIB) in cotransfection assays with Nef.
Nef-mediated redistribution of MHCI, CD80, or CD86
was not affected by the presence of DN-RhoA (Figure 2D),
or DN-cdc42 (Figure 2E). However, DN-Rac1 inhibited
Nef-mediated CD80 and CD86 relocation without affect-
ing MHCI downmodulation (Figure 2F). Further, the CRIB
domain of WASP also caused partial blockade of Nef-
mediated CD80 and CD86 relocation without affecting
the loss of surface MHCI (Figure 2G).
To confirm the role of Rac, we used commercially avail-
able validated rac-specific siRNA or control nonspecific
sequences in cotransfection assays with Nef. The rac-
specific siRNA reduced the cellular levels of Rac but
not of p38MAPK (Figure 2H). Nef-mediated loss of cell-
surface MHCI, CD80, or CD86 was not affected by the
control sequence, but the rac-specific siRNA inhibited
Nef-mediated loss of surface CD80 and CD86, without
affecting the reduction in MHCI levels (Figure 2I).
Activation and Translocation of Src Kinase Is Critical
for Nef-Mediated CD80 and CD86 Internalization
To examine the role of signaling enzymes involved in
phosphorylation cascades, we tested a protein kinase C
(PKC) inhibitor, calphostin C (CC) (Kobayashi et al., 1989),
and a Src tyrosine kinase family inhibitor, PP2 (Hanke
et al., 1996), on Nef-mediated loss of CD80 and CD86 in
U937 cells. Both PP2 (10 mM) and CC (3 mM) separately in-
hibited Nef-mediated CD80/CD86 downmodulation, but
not that of MHCI (Figure 3A). At lower concentrations, nei-
ther PP2 (1 mM) nor CC (0.5 mM) could affect Nef-mediated
loss of surface CD80 and CD86 by themselves, but to-
gether they still blocked this reduction (Figure 3A), sug-
gesting that the two pathways may be working in tandem.
Neither drug affected cell viability over the assay period
(Figure S2).
We next tested the ability of WT Src and three Src mu-
tants, a constitutively active one (CA-Src; Y529F mutant),
a DN one (DN-Src; K296R, Y528F double mutant), and a
kinase-inactive one (KD-Src; K279R mutant), to block
Nef-mediated redistribution of MHCI, CD80, and CD86
using cotransfection assays. WT-Src or CA-Src did not
block Nef-mediated relocation of MHCI, CD80, or CD86
(Figure 3B). However, both KD-Src and DN-Src blocked
Nef-mediated redistribution of CD80 and CD86 but not
MHCI (Figure 3B).
To confirm the role of Src, we used commercially avail-
able validated src-specific siRNA or control nonspecific
sequences in cotransfection assays with Nef. The src-
specific siRNA reduced the cellular levels of Src protein
but not those of other Src family proteins, Hck and Fyn
(Figures 3E and 3F). Nef-mediated redistribution of
MHCI, CD80, or CD86 was not affected by the control
siRNA sequence, but the src-specific siRNA inhibited
Nef-mediated reduction of surface CD80 and CD86 with-
out affecting MHCI downmodulation (Figure 3G). Two
other src-specific siRNAs (Trevino et al., 2005) also gave
similar results (data not shown).c.
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Nef-Mediated Removal of Surface CD80 and CD86Figure 3. Role of Src and PKC in Nef-Mediated Relocation of CD80 and CD86
(A) U937 cells transfected to express either eGFP (yellow shaded curves) or F2-Nef-eGFP were treated with PP2 (10 mM or 1 mM as shown) and
calphostin C (3 mMor 0.5 mMas shown) together or in combination as indicated and stained for surface levels of MHCI, CD80, and CD86. Single-color
histograms of gated eGFP+ cells are shown. Gray curves are isotype controls.
(B) U937 cells were cotransfected for expression of Nef and various Src mutants and stained for cell-surface MHCI, CD80, or CD86. Single-color
histograms show surface staining profiles of MHCI, CD80, or CD86 in gated HAp+ cells (yellow curves), or F2-Nef-Hap+ cells, or F2-Nef-Hap+
WT-Src+/CA-Src+/DN-Src+/KD-Src+ cells as indicated. Gray curves are isotype controls.
(C) U937 cells were cotransfected with either src-specific siRNA or a control nonspecific sequence, and a marker myc-p-expressing plasmid, and
cells were fixed, permeabilized, and stained for the expression of Src and myc-p. The data show two-color diagrams indicating the levels of Src pro-
tein in myc-p-expressing cells.
(D) U937 cells were cotransfected with either Src-specific siRNA or control nonspecific sequences with a marker Thy-1-expressing plasmid, and
magnetic sorting was followed by Western blot analyses of cell lysates with the indicated antibodies.
(E) U937 cells were cotransfectedwith indicated constructs and stained for cell-surfaceMHCI, CD80, or CD86. Single-color histograms show staining
profiles of cells expressing eGFP (yellow curves), F2-Nef, and F2-Nef with either irrelevant c-siRNA or Src-siRNA (detected by expression of myc-p
from a cotransfected myc-p-bearing plasmid). Gray curves are isotype controls.Hierarchy of Nef-Mediated Signals Mediating CD80
and CD86 Internalization
In determining the sequence of signaling steps involved in
Nef-mediated CD80 and CD86 removal, we began by
examining whether CA-Src was capable of reversing the
inhibitory effects of LB, DN-Rac1, or CC. In cotransfection
assays, CA-Srcwas unable to rescue either LB-induced or
DN-Rac-induced inhibition of Nef-mediated CD80/CD86
downmodulation, but it did overcome the blocking effect
of CC (Figures 4A and 4B). These data indicate that PKC
is upstream, while Rac activation and actin polymerization
are downstream of Src activation during Nef-mediated
CD80/CD86 downmodulation. Such a role for PKC in con-
trolling Src activation is consistent with the ability of low
concentrations of PP2 and CC together to block Nef-
mediated CD80/CD86 relocation.
Upon activation, Src undergoes actin-dependent trans-
location to the plasma membrane (Sandilands et al.,
2004). To examine whether Src was translocated in Nef-
expressing cells, we cotransfected U937 cells to expressCellboth Nef andWT-Src. The proportion of total cellular Src in
the cell periphery was quantified (see Experimental Proce-
dures). In eGFP-expressing cells, WT-Src was distributed
perinuclearly (Figures 4C, 4D, 4F, and 4G), while it was
redistributed to the cell periphery in Nef-expressing cells
(Figures 4C and 4D). LB or CC prevented the peripheral
redistribution of WT-Src by Nef (Figures 4C and 4D), indi-
cating that both actin polymerization and PKC activity are
required for Nef-mediated peripheralization of WT-Src. In
contrast, CA-Src was located mainly at the cell periphery
in normal cells, and LB redistributed CA-Src to the peri-
nuclear region, while CC did not affect the peripheral
distribution of CA-Src (Figure 4E), implicating actin poly-
merization but not PKC activation in maintaining CA-Src
at the cell periphery.
We next examined whether DN-Rac1 or CRIB, which
inhibit Nef-mediated CD80 and CD86 downmodulation,
would inhibit Nef-mediated relocation of WT-Src to the
cell periphery. Neither DN-Rac1 nor CRIB had any effect
on Nef-induced plasma membrane relocation of WT-SrcHost & Microbe 1, 37–49, March 2007 ª2007 Elsevier Inc. 41
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Nef-Mediated Removal of Surface CD80 and CD86Figure 4. Role of PKC and Actin in Src Activation and Translocation for Nef-Mediated Relocation of CD80 and CD86
(A) U937 cells, cotransfected to express F2-Nef-HAp, DN-Rac1-eGFP, and CA-Src-myc-p in combinations as indicated, were stained for cell-surface
MHCI, CD80, or CD86. Single-color histograms show surface staining profiles of GFP+ gated cells from eGFP-expressing cells (yellow curves) or from
cells gated for the expression of the indicated molecules. Gray curves are isotype controls.
(B) U937 cells cotransfected to express either eGFP (yellow curves), F2-Nef-eGFP, or CA-Src-myc were incubated without or with either latrunculin B
(LB; top panel) or calphostin C (calC; bottom panel) and stained for cell-surface MHCI, CD80, or CD86. Single-color histograms show surface staining
profiles of cells gated as indicated. Gray curves are isotype controls.
(C) U937 cells cotransfected to express WT-Src-myc-p and either eGFP (top panel) or F2-Nef-eGFP (bottom panel) were treated for 24 hr without ()
or with latrunculin B or calphostin C as indicated. Cells were then fixed and stained for myc-p-tagged WT Src. Scale bar, 10 mm.
(D) The distribution of Src was quantified in the images of U937 cells from (C) above, and data are expressed as the fraction of total Src in the pe-
ripheral half of the cell (mean ± SE; n = 30 cells).
(E) U937 cells transfected for expression of CA-Src-myc-p (green) were treated for 24 hr without () or with latrunculin B or calphostin C and fixed and
stained for MHCI (red). Scale bar, 10 mm.
(F) U937 cells were cotransfected for expression of F2-Nef (blue), WT-Src (red), and either WT-Rac1, DN-Rac1, or CRIB (green) and imaged. Scale
bar, 10 mm.
(G) The distribution of Src was quantified in the images of U937 cells from (F) above and expressed as the fraction of total Src in the peripheral half of
the cell (mean ± SE; n = 30 cells).(Figure 4F and 4G), suggesting that Rac and CRIB domain
protein/s function downstream of Src activation and trans-
location.
We used biochemical analyses to confirm the hierarchy
of Nef-mediated signaling events. U937 cells expressing
Nef showed increased PKC activity (Figure 5A). Further,
while CC blocked Nef-mediated enhancement of PKC ac-
tivity as expected, neither PP2 nor LB blocked it (Fig-
ure 5A), placing Nef-mediated enhancement of PKC activ-
ity upstream of Src activation and actin polymerization.
Immunoprecipitation and Western blot analysis showed
that PKC was coprecipitated with Nef, consistent with
previous reports (Bodeus et al., 1995; Smith et al., 1996),
and that this association was resistant to treatment with
CC, PP2, or LB (Figure 5B).
Western blot analysis of Nef-expressing cells showed
increased levels of tyrosine (Tyr418)-phosphorylated Src
(pSrc), a hallmark of activated Src (Figure 5C). CC blocked
Nef-mediated enhancement of pSrc levels (Figure 5C),
placing Src phosphorylation downstream of PKC activity.
While PP2 reduced pSrc levels as expected, LB did not do42 Cell Host & Microbe 1, 37–49, March 2007 ª2007 Elsevier Inso, indicating that actin polymerization, required for Src
peripheralization, was downstream of Src activation
(Figure 5C).
Rac activation by Nef was assayed by affinity precipita-
tion of activated Rac by beads coated with the Rac-bind-
ing domain of the p21 kinase-binding domain (PAK-PBD),
which binds specifically to activated Rac, followed by
Western blotting with anti-Rac antibody. Total cellular
Rac levels were assayed by using anti-Rac antibody for
immunoprecipitation and Western blotting. Nef-express-
ing U937 cells showed enhanced levels of activated
Rac, but no change in total Rac levels (Figure 5D). Nef-
mediated enhancement of Rac activation was blocked
by treatment of cells with CC, PP2 as well as LB
(Figure 5D), placing Rac activation downstream of Nef-
mediated Src activation and peripheralization.
A possible link between Src and Rac activation was
suggested by the reported Src-driven activation of
TIAM, a guanine nucleotide exchange factor (GEF) for
Rac (Servitja et al., 2003). We tested the ability of a
dominant-negative mutant of TIAM (DN-TIAM [Toliasc.
Cell Host & Microbe
Nef-Mediated Removal of Surface CD80 and CD86Figure 5. Cascade of PKC, Src, TIAM, and Rac Activation in Nef-Mediated Downmodulation of CD80 and CD86
(A–D) U937 cells transfected with either nef or control plasmids with or without treatment with CC (3 mM), PP2 (10 mM), or LB (5 mM) as indicated were
used. In (A), lysates were assayed for PKC activity ([A]; data are mean ± SE of triplicate cultures). In (B), lysates were affinity precipitated with anti-Nef
antibody, followed byWestern blotting with anti-PKC or anti-Nef antibodies. In (C), lysates wereWestern blotted with anti-Src or anti-pSrc antibodies.
In (D), lysates were affinity precipitated with either PAK-PBD or anti-Rac antibody, followed by Western blotting with anti-Rac antibody.
(E) U937 cells were cotransfected with various plasmids and stained for cell-surface MHCI, CD80, or CD86. Single-color histograms show staining
profiles of cells expressing control eGFP (yellow curves), F2-Nef (black lines), WT-TIAM (blue lines, middle panel), DN-TIAM (red lines, middle panel),
F2-Nef+WT-TIAM (blue lines, bottom panel), or F2-Nef+DN-TIAM (red lines, bottom panel). Gray curves are isotype controls.
(F) U937 cells were transfected to express Nef with or without DN-TIAM as indicated. Cell lysates were affinity precipitated with either PAK-PBD or
anti-Rac antibody, and the precipitates were Western blotted with anti-Rac antibody.
(G) U937 cells were transfected to express Nef with or without DN-TIAM as indicated. Cell lysates were Western blotted with anti-pSrc antibody.
(H) U937 cells were transfected to express Nef with or without indicated drugs. Cell lysates were affinity precipitated with anti-TIAM antibody, and the
precipitates were Western blotted with anti-pTyr antibody.et al., 2005]) to block Nef-mediated redistribution ofMHCI,
CD80, and CD86, using cotransfection assays. WT-TIAM
did not block Nef-mediated relocation of MHCI, CD80,
or CD86 (Figure 5E), while DN-TIAM blocked Nef-medi-
ated redistribution of CD80 and CD86 but not MHCI
(Figure 5E).
We next tested a prediction from these data, that TIAM
activity was needed for Nef-mediated Rac activation. DN-
TIAM reduced Rac activation in Nef-expressing cells
(Figure 5F) without affecting the enhanced pSrc levels
(Figure 5G), placing TIAM activity upstream of Rac activa-
tion but downstream of Src activation. We also confirmed
that Nef-expressing cells showed TIAM activation by
Western blotting immunoprecipitated TIAM for tyrosine
phosphorylation. The enhanced tyrosine phosphorylationCellof TIAM in Nef-expressing cells was blocked by inhibition
of PKC, Src, or actin polymerization (Figure 5H).
We examined if the blockade of Nef-mediated CD80/
CD86 downmodulation by DN-TIAM could be reversed
by coexpression of dominant-active Rac (DA-Rac; V12),
using three-way cotransfection assays. U937 cells trans-
fected with nef acquired a subpopulation showing re-
duced surface expression of MHCI, CD80, and CD86 as
expected (Figure 6A; typically 25%, reflecting the trans-
fection efficiency achieved; note: Nef is not marked in any
way in this experiment). However, if these cells were co-
transfected to express DN-TIAM along with Nef, this
CD80-low, CD86-low subpopulation disappeared, al-
though the MHCI-low cells remained (red lines in Fig-
ure 6A, lower panels indicate cells gated for DN-TIAMHost & Microbe 1, 37–49, March 2007 ª2007 Elsevier Inc. 43
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Nef-Mediated Removal of Surface CD80 and CD86Figure 6. Nef Contributes a Rac Activation-Independent
Function to Mediate CD80 and CD86 Downmodulation
(A) U937 cells were cotransfected with various plasmids and stained
for cell-surface MHCI, CD80, or CD86. The two-parameter plots
show staining profiles of cells transfected for Nef expression with or
without DN-TIAM or DA-Rac as indicated. While cells have been gated
for expression of DA-Rac and/or DN-TIAM as indicated, no gating has
been done for Nef expression. The Nef-expressing subpopulation can
be seen as MHCI-low, CD80-low, and CD86-low. Single-color histo-
grams show staining profiles of cells transfected to express control
eGFP (yellow curves) or F2-Nef (black lines), as well as other popula-
tions gated as indicated. The frequency of cells showing MHCI/
CD80/CD86 downmodulation is also shown. Gray curves are isotype
controls.
(B) U937 cells were cotransfected with various plasmids and stained
for cell-surface MHCI, CD80, or CD86. Single-color histograms show
staining profiles of cells expressing control HAp (yellow curves),
F2-Nef-HAp (black lines), F2-Nef and src-siRNA (red lines), or F2-
Nef+src-siRNA+DA-Rac (blue lines). Gray curves are isotype controls.
(C) U937 cells were cotransfected with various plasmids and stained
for cell-surface MHCI, CD80, or CD86. Single-color histograms show
staining profiles of cells expressing control HAp (yellow curves), or ex-
pressing F2-Nef-HAp (black lines), or expressing F2-Nef and treated
with LB (blue lines), or expressing F2-Nef+DA-Rac and treated with
LB (red lines). Gray curves are isotype controls.44 Cell Host & Microbe 1, 37–49, March 2007 ª2007 Elsevier Incotransfected with unmarked Nef). These data show that
Nef remained functional for MHCI relocation, although
DN-TIAM inhibited downmodulation of CD80/CD86.
Furthermore, expression of DA-Rac in these DN-TIAM-
expressing cells restored the ability of Nef to downmodu-
late CD80 and CD86 (blue lines in Figure 6A, lower panel).
However, expression of DA-Rac alone did not lead to any
downmodulation of MHCI, CD80, or CD86 (green lines in
Figure 6A, upper panel), indicating that Nef contributes
functions other than Rac activation to induce endocytosis
of CD80 and CD86.
We also examined if DA-Rac could rescue the Src-
knockdown-mediated blockade in the loss of Nef-driven
CD80/CD86 relocation. U937 cells transfected with Nef
showed reduction of MHCI, CD80, and CD86, and co-
transfection with src-siRNA blocked the loss of surface
CD80 and CD86 as expected. Coexpression of DA-Rac,
however, overcame the Src knockdown-mediated block
and permitted Nef to downmodulate CD80/CD86 (Fig-
ure 6B), demonstrating that Src activation is required
only for Rac activation in this pathway.
Since our data showed that actin was essential to medi-
ate Src translocation to the cell periphery (Figures 4C and
4E), we next examined if actin polymerization was also
needed downstream of Rac activation for Nef-mediated
CD80/CD86 internalization. Nef-expressing U937 cells
showed reduction of MHCI, CD80, and CD86, and LB ab-
rogated the loss of surface CD80 and CD86 as expected.
If actin polymerization were required only for Src translo-
cation and subsequent Rac activation, then coexpression
of DA-Rac would overcome the LB-mediated block and
permit Nef to downmodulate CD80/CD86. However, this
was not the case (Figure 6C), demonstrating that actin po-
lymerization is also required downstream of Rac to allow
Nef to induce CD80/CD86 internalization.
Nef Directly Binds to CD80 and CD86
to Trigger Internalization
Since DA-Rac alone does not induce CD80/CD86 reloca-
tion, other functions of Nef are likely to be needed. We
have previously observed that Nef directly interacts with
full-length CD80 and CD86 (Chaudhry et al., 2005). The
coimmunoprecipitation of CD80 or CD86 with Nef was in-
sensitive to CC, PP2, and LB treatment (Figure 7A). There-
fore, we hypothesized that Nef binds the cytoplasmic tails
of CD80 and CD86 to facilitate their internalization.
To test this hypothesis, we examined whether Nef di-
rectly bound to a synthetic peptide corresponding to the
cytoplasmic tail of human CD80 (CD80cytpep). Recombi-
nant Nef bound efficiently to immobilized CD80cytpep,
but not to three irrelevant peptides or to BSA (Figure 7B).
Further, in an inhibition assay, nanomolar concentrations
of soluble CD80cytpep inhibited Nef binding to the immo-
bilized peptide (Figure 7C), consistent with a high-affinity
interaction. We therefore introduced CD80cytpep into
Nef-expressing U937 cells using the Chariot reagent at
4C. Intracellular CD80cytpep caused substantial reduc-
tion in the loss of CD80 (but not of CD86 or MHCI) from
the surface of Nef-expressing cells (Figure 7D). Thus,c.
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Nef-Mediated Removal of Surface CD80 and CD86Figure 7. Nef Binds to the Cytosolic Tails of CD80 and CD86 to Mediate Their Internalization
(A) Lysates of U937 cells transfected with either nef or control plasmids with or without treatment with CC, PP2, or LB as indicated were immunopre-
cipitatedwith anti-Nef antibody followed byWestern blottingwith anti-CD80 or anti-CD86 antibodies. Cell lysateswere alsoWestern blottedwith anti-
CD80 or anti-CD86 antibodies as input controls.
(B) CD80cytpep or three irrelevant peptides (OT-I epitope peptide SIINFEKL, OT-II epitope peptide ISQAVHAAHAEINEAGR, and p14 epitope peptide
KAVYNFATM), or BSA, were coated on polystyrene plates, recombinant Nef protein was added, and bound protein was detected as absorbance at
492 nm using labeled anti-Nef antibody. Data are expressed as mean ± SD (n = 3).
(C) CD80cytpep was coated on polystyrene plates, recombinant Nef protein was added (3 mg/ml) in the presence or absence of titrating concentra-
tions of inhibitor peptides as indicated, and bound Nef protein was detected as above. The data are expressed as percent inhibition (mean ± SD; n = 3)
caused by the inhibitor peptides at each concentration.
(D) U937 cells transfected for expression of control eGFP alone or F2-Nef-eGFP were cytosolically loaded with CD80cytpep by the Chariot reagent,
and stained for cell-surface MHCI, CD80, or CD86. Single-color histograms show surface staining profiles of eGFP+ gated cells from cultures trans-
fected for expression of eGFP alone (yellow curves) or F2-Nef-eGFP (black lines), or cells loaded with an irrelevant peptide (SIINFEKL; blue lines) or
with CD80cytpep (red lines). Gray curves are isotype controls.
(E) CD86cytpep (A, B, or C), or an irrelevant peptide (OT-II epitope peptide ISQAVHAAHAEINEAGR), or BSA, was coated on polystyrene plates, re-
combinant Nef protein was added, and bound protein was detected as in (B) above. Data are expressed as mean ± SD (n = 3).
(F) U937 cells transfected for expression of control eGFP alone or F2-Nef-eGFPwere cytosolically loaded with CD86cytpepA+B, or CD86cytpepC, by
the Chariot reagent, and were stained for cell-surface MHCI, CD80, or CD86. Single-color histograms show surface staining profiles of gated eGFP+
cells from cultures transfected for expression of eGFP alone (yellow curves) or F2-Nef-eGFP (black lines), or cells loaded with CD86cytpepC (blue
lines), or with CD86cytpepA+B (red lines). Gray curves are isotype controls.Nef interaction with the cytosolic tail of CD80 is required to
trigger its internalization.
We also tested if Nef directly bound to synthetic pep-
tides corresponding to the cytoplasmic tail of human
CD86. Since the cytosolic tail of human CD86 is a 60 res-
idue peptide, we used three synthetic peptides represent-
ing the 20-mer terminal sequence (CD86cytpepA), the
intermediate 20 residue sequence (CD86cytpepB), and
the membrane-proximal 20-mer sequence (CD86cyt-
pepC). Nef bound efficiently to immobilized CD86cyt-
pepA, showed very marginal binding to CD86cytpepB,
and did not bind to CD86cytpepC or to an irrelevant pep-Cetide (OT-IIpep) or to BSA (Figure 7E). We therefore intro-
duced an equimolar mixture of CD86cytpepA and
CD86cytpepB into Nef-expressing U937 cells using the
Chariot reagent at 4C. The presence of intracellular
CD86cytpepA+B led to a substantial reduction in the
downmodulation of surface CD86 (but not of CD80 or
MHCI) in Nef-expressing cells (Figure 7F), showing that
Nef interaction with the cytosolic tail of CD86 is required
to trigger its internalization. These data also suggest that
CD80 and CD86 bind to nonoverlapping regions of Nef.
Since Src is activated by Nef in a perinuclear location,
we hypothesized that the ability of Nef to activate thell Host & Microbe 1, 37–49, March 2007 ª2007 Elsevier Inc. 45
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Nef-Mediated Removal of Surface CD80 and CD86PKC-Src-TIAM-Rac pathway was independent of its abil-
ity to bind to the cytosolic tails of CD80/CD86. To test this,
we examined a number of Nef mutants for these two prop-
erties. One point mutant of Nef, D123G-Nef, showed dis-
cordance between these two properties. BothWTNef and
D123G-Nef similarly induced PKC activity in transfected
cells (Figure 8A), and activated Src (Figure 8B) as well as
Rac (Figure 8C). However, unlike WT Nef, D123G-Nef
could not either mediate efficient loss of cell-surface
CD80 or CD86 (Figure 8D), or bind to the cytosolic tail
peptides of CD80 or CD86 (Figure 8E). Thus, Nef mediates
endocytosis of cell-surface CD80 and CD86 by a two-
pronged mechanism, by activating the PKC-Src-TIAM-
Rac pathway on the one hand to trigger Rac-mediated
endocytosis, and on the other hand by binding to the
cytosolic tails of CD80 and CD86 to mark these molecules
for Rac-mediated endocytosis.
DISCUSSION
Our results show that, in addition to MHCI and CD4, HIV
Nef protein also mediates the removal of the major cell-
surface costimulatory molecules CD80 and CD86 in
monocytic cells by the adoption of an unusual endocytic
program, for which we propose a molecular mechanism
based on our data (see Figure 8F). Preliminary experi-
ments to test the possibility that Nef may also modify exo-
cytosis of newly synthesized CD80 and CD86 to the cell
surface have revealed no such effect of Nef, although
Nef does affect the rate of MHCII exocytosis (unpublished
data). Thus, Nef-induced endocytosis of cell-surface
CD80/CD86 mediates the reduction in surface levels of
these molecules. This Nef-induced endocytic program re-
moving cell-surface CD80 and CD86 differs substantially
from that used to remove cell-surface MHCI, even though
CD80, CD86, and MHCI all appear to be delivered to the
same intracellular compartment in Nef-expressing cells
(Chaudhry et al., 2005).
CD80 and CD86 internalization appears to result from
two distinct sets of Nef activity in different cellular loca-
tions. At the cell surface, Nef-mediated internalization of
surface CD80 or CD86 is dependent on the binding of
Nef to the cytosolic tail of the target molecule; introduction
of CD80cytpep or CD86cytpep, which would compete for
such binding, substantially reduces CD80 or CD86 inter-
nalization, respectively. Indeed, introduction of the tail
peptides into Nef-expressing U937 cells reduces the ex-
tent of coimmunoprecipitation of the homologous target
molecule with Nef (unpublished data). Thus, CD80 and
CD86 cytosolic tails appear to have distinct binding sites
on Nef and block the effect of Nef in a target molecule-
specific fashion by competition for binding rather than
through global sequestration of Nef.
Actin recruitment to the Nef-marked CD80 and CD86 is
necessary for completion of the internalization process.
Inhibitors of actin polymerization, as well as a subset of
molecules such as DN-Rac (or rac-siRNA) and the CRIB
domain of WASP, which interfere with recruitment of
actin nucleators, inhibit Nef-mediated CD80/CD8646 Cell Host & Microbe 1, 37–49, March 2007 ª2007 Elsevier IFigure 8. A Mutant Nef Activates Rac but Cannot Bind to
CD80/CD86 or Induce Their Internalization
(A–C) U937 cells transfected with either WT nef, G2A nef, D123G nef,
or control plasmids as indicated were used. In (A), lysates were as-
sayed for PKC activity (data as mean ± SE of triplicate cultures). In
(B), lysates wereWestern blotted with anti-Src or anti-pSrc antibodies.
In (C), lysates were affinity precipitated with either PAK-PBD or anti-
Rac antibody, followed by Western blotting with anti-Rac antibody.
(D) U937 cells were cotransfected with various plasmids and stained
for surfaceMHCI, CD80, or CD86. Single-color histograms show stain-
ing profiles of cells expressing control eGFP (yellow curves), F2-Nef
(black lines), or D123G-Nef (blue lines). Gray curves are isotype
controls.
(E) CD80cytpep or CD86cytpepA was coated on polystyrene plates,
recombinant WT Nef or D123G-Nef or G2A-Nef proteins were added,
and bound protein was detected as in Figure 7B above. Data are ex-
pressed as mean ± SD (n = 3).
(F) Model depicting the proposed two-pronged mechanism of Nef-
induced CD80 and CD86 endocytosis. A model consistent with the
data suggests that Nef binds to the cytoplasmic tail of CD80 (and
CD86) and tags these molecules for internalization (blue arrow). The
actual internalization process requires Rac-dependent actin polymer-
ization. Nef achieves Rac activation by activating intracellular Src. Nef-
mediated activation of Src involves PKC and actin-dependent Src
translocation to the cell periphery. Activated Src in the cell periphery
triggers TIAM, which in turn facilitates Rac activation.nc.
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CRIB domain for cdc42, cdc42 is not involved in Nef-
mediated CD80/CD86 endocytosis. However, it is possi-
ble that the WASP CRIB domain is able to inhibit Rac-
dependent events, albeit at a lower efficiency, explaining the
finding that the WASP CRIB domain mediates only partial
blockade of Nef-mediated CD80/CD86 endocytosis.
Consistent with previous reports of Nef-Rac interaction
(Janardhan et al., 2004), we find that Nef and Rac are co-
precipitated (data not shown). The significance of this in-
teraction for the Nef-mediated downmodulation of CD80
and CD86 is presently unclear, although it may be relevant
for Nef-directed delivery of tagged CD80 and CD86 to
actin polymerization nucleation sites at the cell surface.
Since DA-Rac does not induce any loss of cell-surface
CD80/CD86 on its own, and since D123G-Nef activates
Rac but does not bind to or downmodulate CD80/CD86,
Nef-mediated marking of CD80 and CD86 is essential
for internalization.
While the significance of PI3K activity in Nef-mediated
MHCI redistribution is controversial (Larsen et al., 2004),
our data indicate that the role of PIK activity in Nef-medi-
ated CD80/CD86 reduction is distinct from its role inMHCI
reduction; CD80/CD86 relocation is unaffected even at
the high Wm concentration that prevents Nef-mediated
surface MHCI loss. Wm inhibits other PIKs in addition to
PI3K at high concentrations (Wymann et al., 1996). There-
fore, while some PIKs may be involved in MHCI down-
modulation by Nef, CD80/CD86 endocytosis by Nef is
likely to be independent of a variety of PI or higher-order
PIP kinases, ruling out a significant role for PIP generation
as a site of actin activation in this endocytic process.
Instead, our results suggest a pivotal role for Nef-medi-
ated activation of Src and its relocation to the cell periph-
ery for mediating CD80/CD86 downmodulation, since the
kinase-inactive Src mutants and siRNA-mediated Src
knockdown inhibit Nef-mediated CD80/CD86 endocyto-
sis, and since Nef-expressing cells show Src activation.
In fact, unlike other reports (Suzu et al., 2005; Trible
et al., 2006), we have been unable to demonstrate activa-
tion of other Src family kinases, Hck and Fyn, in Nef-
expressing U937 cells (data not shown), possibly due to
some cell-lineage specificity in these events. However, re-
gardless of the phosphorylation status of Hck or Fyn, our
data show that Src itself is essential for Nef-mediated
CD80/CD86 downmodulation and cannot be substituted
by any other Src family kinase, even though these are ex-
pressed and are not perturbed by the src-specific siRNA.
Our observations that Nef-triggered Src activation is
PKC dependent, that nef-transfected cells show en-
hanced levels of PKC activity, and that PKC coprecipi-
tates with Nef, are all consistent with the reported interac-
tion of PKC and Nef through the RACK1 adaptor protein
(Gallina et al., 2001), which may also provide a platform
for Src activation. Again, consistent with previous data
that Nef interacts with Src family kinases (Trible et al.,
2006), we find that Nef and Src are coprecipitated (data
not shown), but the role of this interaction in Nef-mediated
CD80/CD86 downmodulation is presently unclear. TheCNef-Src interaction appears to be independent of Src
activation, and phosphorylated Src is not specifically ex-
cluded from interacting with Nef (see Figure S3). In any
event, the ability of plasma membrane-localized CA-Src
to overcome blockade by PKC inhibition, and the localiza-
tion of WT-Src at the cell periphery in Nef-expressing cells
compared to its perinuclear location in eGFP-expressing
cells, provide support for a role for Src redistribution
from a perinuclear location to a peripheral one in Nef-
mediated CD80 and CD86 internalization. The transloca-
tion is a consequence of its activated state, since CA-Src
is located at the cell periphery even in the absence of Nef,
consistent with previous studies (Sandilands et al., 2004).
These results also suggest two roles for actin in facilitat-
ing CD80/CD86 internalization. Actin polymerization is
required for peripheralization of PKC-activated-Src. Actin
also plays a role downstream of Src translocation in CD80
and CD86 endocytosis, since DN-Rac and CRIB inhibit
CD80 and CD86 internalization without affecting the Nef-
mediated peripheralization of activated Src, and since
DA-Rac is unable to overcome the LB-induced block of
Nef-mediated CD80/CD86 relocation.
Finally, a direct link between Nef-induced activation of
Src and Rac appears to be the GEF for Rac, TIAM, since
TIAM is phosphorylated in nef-transfected cells, since
DN-TIAM expression inhibits Nef-induced Rac activation
as well as CD80 andCD86 internalization without affecting
Src activation, and since the effect of DN-TIAM is over-
come by DA-Rac.
The lack of a role for dynamin in Nef-mediated CD80
and CD86 endocytosis and the insensitivity of this endo-
cytosis event to membrane cholesterol depletion, to-
gether with the Src-activated actin-dependent elements
required for Nef-mediated relocation of CD80 and CD86,
constitute an unusual endocytic program. Some elements
of this endocytic process resemble the ‘‘caveolar-like’’
pathway used for the internalization of simian virus 40
(SV40), due to its dependence on Src and actin (Pelkmans
et al., 2002). Nef-mediated relocation of CD80 and CD86
is also dynamin independent, as reported earlier for
MHCI, and similar to the situation with SV40 in caveolin-
1-negative cells (Damm et al., 2005) such as those of the
myeloid lineage. However, unlike SV40 or Nef-mediated
MHCI internalization, Nef-mediated endocytosis of CD80
and CD86 is cholesterol independent. This aspect of the
Nef-mediated downregulation of CD80/CD86 resembles
the clathrin-, caveolae-, and dynamin-independent inter-
nalization mechanism of polyoma virus in receptor-
negative cells (Gilbert et al., 2005). The specific linking of
this endocytic machinery to Nef-marked cell-surface
CD80/CD86 remains a unique feature.
We have recently observed that gated ion channels are
internalized upon antagonist application by a pathway
remarkably similar to this Nef-induced pathway in being
dynamin independent and sensitive to the samemolecular
perturbants as the Nef-mediated pathway is (unpublished
data). It is thus likely that such endocytic programs can be
used in the absence of Nef in other physiological situations
to modulate the cell-surface levels of other proteins.ell Host & Microbe 1, 37–49, March 2007 ª2007 Elsevier Inc. 47
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jack Src-dependent actin-mediated trafficking mecha-
nisms to trigger CD80/CD86 removal from the monocytic
cell surface, rendering the macrophage deficient in its ca-
pacity to activate naive T cells. Since HIV-1-infected indi-
viduals have some level of antiviral CD8 T cell immunity,
removal of CD80 and CD86 by Nef clearly does not block
the induction of immune responses completely, although
there is evidence for dysfunctionality of antiviral CD8 T
cell responses in HIV infection (reviewed in Benito et al.,
2004). The role of Nef-mediated CD80 and CD86 down-
modulation could be relevant both during the early stages
of infectionwhen viral load is low and removal of CD80 and
CD86 from the antigen-presenting cell surface could delay
the onset of T cell responses to provide the virus with
a time window for expansion, and even in states of estab-
lished infection where the removal of CD80 and CD86
from infected cell surfaces could reduce the efficiency of
T cell responses, since there is evidence that T cells
need costimulatory molecules for optimal killing of target
cells (Allison et al., 1998; Ramarathinam et al., 1994). If
this is the case, blockade of this function, possibly by
small-molecule inhibitors of Nef-CD80/CD86-cytosolic
tail interactions, could enhance effector antiviral immunity
and delay the onset of disease.
EXPERIMENTAL PROCEDURES
Plasmids, Cell Culture, and Reagents
The F2-nef gene from an Indian HIV-1 subtype C primary isolate subcl-
oned into the bicistronic mammalian expression vector pIRES2-eGFP
(BD Clontech), or expressed as a nef-eGFP fusion gene in the plasmid
peGFP-N3 (BD Clontech), or expressed via the pMT3 expression vec-
tor (BD Clontech) tagged with the influenza virus hemagglutinin (HAp)
epitope, has been described earlier (Chaudhry et al., 2005). See Sup-
plemental Experimental Procedures for details of other plasmids, cell
culture, and reagents, and for the sources of reagents and monoclonal
antibodies (mAbs), cell labeling, and treatments used. U937, a human
monocytic lineage cell line, was transfected as described (Chaudhry
et al., 2005) and stained for flow cytometric analysis 16–24 hr post-
transfection. All drug treatments were also for 16–24 hr. All surface
labeling was done at 8 hr posttransfection.
Confocal Imaging, Flow Cytometry, Immunoprecipitation
and Affinity Precipitation, and Western Blot Analyses
Flow cytometry, immunoprecipitation, andWestern blot analyses were
performed as described (Chaudhry et al., 2005; also see Supplemental
Experimental Procedures). A marker Thy-1-expressing plasmid was
cotransfected with nef plasmids to enable magnetic sorting (Miltenyi,
Germany) of successfully transfected cells for biochemical analyses.
Sorted cell lysates were Western blotted for Nef expression levels
(see Figure S4). It may be noted that the punctuate nature of eGFP dis-
tribution is a function of high-contrast confocal imaging, and the extent
of punctuate fluorescence varies from cell plane to cell plane.
Quantitative Fluorescence Distribution Analysis
For observing Src peripheralization, high-resolution images of cells
were obtained using a 603 1.4 NA objective on a wide-field micro-
scope or confocal microscope at a pixel resolution of 0.15 mm/pixel
as detailed in the Supplemental Experimental Procedures. The images
were corrected for background fluorescence using the ‘‘produce
background correction’’ image procedure in Metamorph image analy-
sis software using the following parameters (box size = 303 30 pixels;
subsample ratio = 10; percentile = 0.2). For Src peripheralization quan-48 Cell Host & Microbe 1, 37–49, March 2007 ª2007 Elsevier Itification, the cell outline was marked, and total fluorescence within it
was quantified. The central area of the cell was marked by proportion-
ate 50% reduction of the cell boundary along both x and y cell axes,
and Src fluorescence outside this area was quantified. The ratio of
peripheralized Src was determined from these values. All analyses
used MetaMorph software.
CD80 and CD86 Cytosolic Tail Peptide-Binding Assays
Enzyme-linked binding assays were used to detect the binding of rF2-
Nef protein to CD80 or CD86 cytosolic tail peptides. The efficiency of
binding was assessed using an inhibition assay. Detailed procedures
are provided (see Supplemental Experimental Procedures). Data
shown are representative of three independent experiments.
Intracellular Delivery of Proteins and Peptides
Briefly, 1 mg of either recombinant Nef or BSA or various peptides
were incubated with 10 ml of the Chariot reagent for 30 min to allow
complex generation, the mixture was overlaid onto 1 3 106 cells on
ice and incubated for 15 min before being washed and shifted to 37C.
PKC Assay
PKC activity was assayed using a commercial kit (Calbiochem). Briefly,
cell lysates were loaded onto an immobilized substrate peptide, and
the resultant Ser/Thr phosphorylation of the substrate was measured
by a specific antibody colorimetrically at 492 nm.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
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